|
|
Vaccine Detail
|
Allogeneic HLA-A2/4-1BB ligand-expressing Melanoma Vaccine |
| Vaccine Information |
- Vaccine Name: Allogeneic HLA-A2/4-1BB ligand-expressing Melanoma Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Live, attenuated vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: HLA-A2/4-1BB Ligand (NCT01861938)
- Immunization Route: Other
- Description: The vaccine consists of an allogeneic cell line that has a high expression level of melanoma molecules (HLA A2/4-1BB Ligand), and has been genetically modified to induce a strong immune response. Stimulation of the immune response against the tumor can help destroy residual tumor in melanoma patients with very high risk for disease recurrence and in patients with relatively low tumor burden who already got first line treatment for their disease. (NCT01861938)
|
| Host Response |
|
|
| References |
NCT01861938: Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients [https://clinicaltrials.gov/study/NCT01861938]
|
|
